Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(06): 360-364
DOI: 10.1055/s-0042-123041
Article
© Georg Thieme Verlag KG Stuttgart · New York

Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine

Robert Krysiak
1   Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
,
Witold Szkróbka
1   Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
,
Bogusław Okopień
1   Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
› Author Affiliations
Further Information

Publication History

received 18 October 2016
revised 18 October 2016

accepted 05 December 2016

Publication Date:
10 January 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Metformin as well as dopaminergic agents exert a beneficial effect on glucose and lipid metabolism, often impaired in patients with hyperprolactinemia.

Objective: The aim of this study was to compare metabolic- and prolactin-lowering effects of low-dose bromocriptine/metformin combination therapy and cabergoline in patients with elevated prolactin levels.

Methods: The study included 27 women with hyperprolactinemia and impaired glucose tolerance who were treated with moderate doses of bromocriptine but experienced adverse effects of this treatment. In 12 of these patients bromocriptine was replaced with cabergoline (group A), while the remaining ones continued treatment with bromocriptine, the dose of which was halved, and administered together with metformin (group B). Plasma lipids, glucose homeostasis markers, as well as serum levels of prolactin, thyrotropin and insulin-like growth factor-1 (IGF-1) were assessed before and after 4 months of metformin treatment.

Results: Both groups did not differ in baseline levels of plasma glucose and lipids, in insulin sensitivity, as well as in circulating levels of all measured hormones. All patients from group A and 12 patients from group B completed the study. Cabergoline reduced prolactin levels, while no effect on plasma prolactin was found in group B. Neither cabergoline nor bromocriptine plus metformin affected circulating levels of thyrotropin and IGF-1. Both treatment options, particularly low-dose bromocriptine plus metformin, improved glucose and lipid homeostasis.

Conclusions: Low-dose bromocriptine combined with metformin may be an interesting alternative to cabergoline in patients with mild hyperprolactinemia and early glucose metabolism abnormalities, in whom moderate doses of bromocriptine are poorly tolerated.

Key words

hyperprolactinemia - impaired glucose tolerance - metformin - pituitary hormones
 

  • References

  • 1 Genuth S.. The UKPDS and its global impact. Diabet Med 2008; 25 (Suppl. 02) 57-62
    CrossrefPubMedGoogle Scholar
  • 2 Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
    CrossrefPubMedGoogle Scholar
  • 3 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diabetes Vasc Dis Res 2008; 5: 157-167
    CrossrefPubMedGoogle Scholar
  • 4 Banks WA. Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinology 2012; 153: 4111-4119
    CrossrefPubMedGoogle Scholar
  • 5 Labbuzek K, Suchy D, Gabryel B. et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010; 62: 956-965
    CrossrefPubMedGoogle Scholar
  • 6 Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91: 225-227
    CrossrefPubMedGoogle Scholar
  • 7 Isidro ML, Penín MA, Nemiña R. et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007; 32: 79-82
    CrossrefPubMedGoogle Scholar
  • 8 Cappelli C, Rotondi M, Pirola I. et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32: 1589-1590
    CrossrefPubMedGoogle Scholar
  • 9 Lupoli R, Di Minno A, Tortora A. et al. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab 2014; 99: E143-E148
    CrossrefPubMedGoogle Scholar
  • 10 Krysiak R, Okopień B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55: 45-49
    CrossrefPubMedGoogle Scholar
  • 11 Krysiak R, Okopień B. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol 2011; 75: 404-406
    CrossrefPubMedGoogle Scholar
  • 12 Oride A, Kanasaki H, Purwana IN. et al. Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs. Pituitary 2010; 13: 236-241
    CrossrefPubMedGoogle Scholar
  • 13 Genazzani AD, Battaglia C, Malavasi B. et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in non-obese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114-119
    CrossrefPubMedGoogle Scholar
  • 14 Krysiak R, Okrzesik J, Okopień B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2015; 49: 242-249
    CrossrefPubMedGoogle Scholar
  • 15 Krysiak R, Kowalcze K, Szkrobka W et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med 2016 Feb 5. pii: S0953-6205(16)00016-9
    PubMed
  • 16 dos Santos Silva CM, Barbosa FR, Lima GA. et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011; 19: 800-805
    CrossrefPubMedGoogle Scholar
  • 17 Kumar V, Aithal S, Baleed SR. et al. Bromocriptine, a dopamine (D2) receptor agonist, used Alone and in combination with glipizide in sub-therapeutic doses to ameliorate hyperglycaemia. J Clin Diagn Res 2013; 7: 1904-1907
    PubMedGoogle Scholar
  • 18 Ciresi A, Amato MC, Guarnotta V. et al. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf) 2013; 79: 845-852
    CrossrefPubMedGoogle Scholar
  • 19 Krysiak R, Okopień B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol 2015; 116: 251-255
    CrossrefPubMedGoogle Scholar
  • 20 Auriemma RS, Granieri L, Galdiero M. et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 2013; 98: 299-310
    CrossrefPubMedGoogle Scholar
  • 21 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48: 547-553
    CrossrefPubMedGoogle Scholar
  • 22 Berinder K, Nyström T, Höybye C. et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207
    CrossrefPubMedGoogle Scholar
  • 23 Doknic M, Pekic S, Zarkovic M. et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147: 77-84
    CrossrefPubMedGoogle Scholar
  • 24 Iván G, Szigeti-Csúcs N, Oláh M. et al. Treatment of pituitary tumors: dopamine agonists. Endocrine 2005; 28: 101-110
    CrossrefPubMedGoogle Scholar
  • 25 Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-1078
    CrossrefPubMedGoogle Scholar
  • 26 Molitch ME. Management of medically refractory prolactinoma. J Neurooncol 2014; 117: 421-428
    CrossrefPubMedGoogle Scholar
  • 27 Weiland CM, Hilaire ML. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus. Am Fam Physician 2013; 87: 718-720
    PubMedGoogle Scholar
  • 28 DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011; 34: 789-794
    CrossrefPubMedGoogle Scholar
  • 29 Ortega-González C, Cardoza L, Coutiño B. et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005; 184: 233-239
    CrossrefPubMedGoogle Scholar